OTHER PUBLICATIONS & ABSTRACTS

Other Data


Evidence / Other

The FLEX real world data platform explores new gene expression profiles and investigator-initiated protocols in early stagebreast cancer

PUBLICATION: SABCS 2020 AUTHORS: Laura Lee, Sami Diab, Julie Barone, Jennifer A. Crozier, Margret Chen, Rakshanda Layeequr Rahman, Robert Maganini, Douglas Marks, Amy M. Truitt, Lisa Blumencranz10, Erin Yoder10, William Audeh, Bastiaan van der Baan, FLEX Investigators Group Background: Genomic expression profiles have implications for the personalized treatment of Read More

ESMO 2020 – Hallmarks of Cancer

PUBLICATION: ESMO 2020 AUTHORS: Josien C. Haan, Rajith Bhaskaran, Lorenza Mittempergher, Ersan Lujinovic, William Audeh, Frederique Penault-Llorca and Annuska M. Glas Background: MammaPrintยฎ (MP) is a 70-gene based assay that stratifies early-stage breast cancer (EBC) patients into low and high-risk of relapse. BluePrintยฎ (BP) is an 80-gene based assay that Read More

Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trial

PUBLICATION: European Journal of Cancer AUTHORS: Valesca P. Retel, Danalyn Byng, Sabine C. Linn, Katarzyna Jozwiak, Hendrik Koffijberg, Emiel J. Rutgers, Fatima Cardoso, Martine J. Piccart, Coralie Poncet, Laura J. van โ€™t Veer, Wim H. van Harten. Abstract: The clinical utility of the 70-gene signature (MammaPrintยฎ) to guide chemotherapy Read More

ASCO 2020: TNBC Subtype

PUBLICATION: ASCO 20 AUTHORS: Virginia G. Kaklamani, Cathy Graham, Karen L. Tedesco, Abirami Sivapiragasam, Jennifer Crozier, Apurva N. Shah, Andrea Menicucci, Shiyu Wang, Michelle L. Bolner, Erin Yoder, William Audeh, FLEX Investigators' Group SUMMARY: Triple negative breast cancer (TNBC) is an aggressive histological subtype with few targeted therapies and worse Read More

ASCO 2020: HER2 Reclassification

PUBLICATION: ASCO 2020 AUTHORS: Adam Brufsky, Jennifer A. Crozier, Paul J. Chuba, Sung Ho Lee, Andrea Menicucci, Heather M. Kling, Erin Yoder, William Audeh, FLEX Investigators' Group SUMMARY: Biological heterogeneity of HER2 positive breast cancers is supported by a modest benefit of HER2- targeted therapies reported in the APHINITY and Read More

ASCO 2020: FLEX Trials in Progress

PUBLICATION: ASCO 20 AUTHORS: Nina Dโ€™Abreo, Jennifer Crozier, Adam Brufsky, Ian Grady, Sami Diab, Blanche Mavromatis, Carrie Dul, Rakhshanda Layeequr Rahman, Laura Lee, Vijayakrishna K. Gadi1, Sarah Untch, Erin Yoder, Heather M. Kling, Amy M. Truitt, William Audeh, Bastiaan van der Baan, FLEX Investigators Group SUMMARY: Genomic expression profiles have Read More